The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

HCC  -  thyroid carcinoma, Hurthle cell

Homo sapiens

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of HCC


Psychiatry related information on HCC


High impact information on HCC

  • IMPLICATIONS: Further studies are needed to clarify potential risk factors, including specific HCV genotypes, for progression to HCC among HCV carriers [8].
  • In FNH, Ang-1 was significantly up-regulated, Ang-2 was down-regulated, and the Ang-1/Ang-2 ratio was highly and specifically increased in FNH compared with normal liver or other groups of lesions (FNH, 15.2-fold increase; HCC, 2.78; adenoma, 2.28; cirrhosis, 1.92; P < 0.01 for FNH vs. all groups, analysis of variance) [9].
  • In looking for such a predisposition, we have compared the histocompatibility antigens (HLA) of 102 southern African blacks with histologically proved HCC with those of 208 healthy blacks [10].
  • The results of studies of the spectra of HCO, trans-HOCO, HCC, C2-, CO2+, CO2-, C2H2+, C3H4+, HCOOH+, HOCO+, and HCO2- summarized in this Account illustrate the importance of supplementing familiar generalizations with experimental observations [11].
  • Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria [12].

Chemical compound and disease context of HCC

  • No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group [13].
  • CONCLUSION: This phase II study of nolatrexed in advanced HCC patients, demonstrated minimal activity and significant stomatitis [14].
  • Data of the long-term benefit of subjects treated with IFN plus ribavirin are still not available; 5) pooling of published data suggests a slight preventive effect of IFN on HCC development in patients with HCV-related cirrhosis [15].
  • This adenovirus, designated Ad.HS4.AFP.E1A/TRAIL, expresses E1A to mediate viral replication and TRAIL to enhance HCC-killing efficacy under the control of a modified AFP promoter [16].
  • The specific rotations of 2-substituted butanes (X = F, Cl, CN, and HCC) were calculated at the B3LYP/aug-cc-pVDZ level as a function of the C-C-C-C torsion angle [17].

Biological context of HCC

  • Forty frozen tumor tissues and 39 paired plasma samples from HCC patients were collected in Taiwan, to determine the relationship between albumin adducts in blood and DNA adducts in liver tissue as well as mutations in p53 and methylation of p16 [18].
  • These data suggest that genetic, epigenetic and environmental exposure biomarkers in plasma may help in estimating the risk for the development of HCC [18].
  • AIM: To study the epidemiology of HCC in Lebanon and prognostic factors predictive of early mortality [4].
  • We investigated Th1/Th2 cytokine production as well as frequency and phenotype of circulating NKT cells in 14 healthy subjects and in patients during therapy with type C chronic hepatitis (CH; 14 cases) and hepatocellular carcinoma (HCC; 13 cases) [19].
  • Although gene expression profiles in HCC derived in all three transgenic lines were highly similar, oncogene-specific gene expression signatures were identified at an early dysplastic stage of hepatocarcinogenesis [20].

Anatomical context of HCC

  • We sought to clarify the prognostic value of preoperative peripheral blood leukocyte subset counts, especially the absolute monocyte count, in HCC patients who have undergone hepatic resection [21].
  • However, biopsy specimens retain value for showing fibrosis/cirrhosis and dysplastic hepatocytes, both of which increase risks of HCC development [22].
  • This cell line, designated Tong/HCC, has been grown in a hormone-supplemented medium for more than 18 months [23].
  • METHODS: Thirty-six consecutive patients with PSC and HBC (32 with bile duct carcinoma, BDC, and four with hepatocellular carcinoma, HCC) were pair-matched to control patients referred for liver transplantation because of PSC but who did not have HBC [24].
  • T cell infiltration and prognosis in HCC patients [25].

Associations of HCC with chemical compounds

  • Independent predictors of early mortality are elevated bilirubin, creatinine and HCC as first manifestation of disease [4].
  • Conclusion: The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo [26].
  • Compared with the paired non-HCC liver tissues, genome-wide 5-methylcytosine content in HCC was reduced in all of the tested HCC samples (P < 0.001) [27].
  • Dietary factors that appear to influence susceptibility to HCC include fat, protein and amino acids, vitamin A, selenium, and zinc [28].
  • Our hypothesis dealt with the possible role of testosterone in the etiology of HCC, which shows a minimum of a 2- to 3-fold male excess in all populations world-wide [29].

Enzymatic interactions of HCC


Co-localisations of HCC

  • RESULTS: Pro-collagen alpha1 (I) mRNA co-localized to alpha-SMA positive hepatic stellate cells within the region of increased collagen deposition in (i) the tumour capsule of encapsulated HCC, and (ii) the tumour junction of non-encapsulated HCC and colorectal metastasis [31].

Regulatory relationships of HCC

  • CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens [32].
  • CONCLUSION: TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade [33].
  • HBxAg, Fas and FasL might express in the same area of carcinoma tissues and this co-expression could be found in most patients with HCC [34].
  • The expression of MARCKS was down-regulated in HCC tissues, as compared with non-tumorous liver cirrhosis tissues from the same patients [30].
  • CONCLUSION: COMP is highly expressed within the tumor cells of HCC, suggesting that COMP might play a role in the pathophysiology of this disease [35].

Other interactions of HCC

  • Although the level of serum VEGF was significantly higher in all HCC patients than in healthy control, no significant difference, however was observed between HCV infected and HCV-free groups [36].
  • To address this, we examined the CAD transcripts in six human HCC cell lines, one liver tissue from a non-HCC subject, and peripheral blood leukocytes (PBL) from three healthy individuals [37].
  • MMP-9 activities of HFH-T2, HepG2-HBV and Hep3B were significantly higher than that of non-HBV-hepatocellular carcinoma SK-Hep1 and HepG2 (HCC origin, HBV not detected), as assayed by gelatin zymography [38].
  • No positive 111In-OCT scans were obtained, indicating the absence of relevant amounts of functional SSTR2 in HCC [39].
  • CONCLUSIONS: Our data suggest a negative effect of an ER(+) tumor on patient survival after curative resection of advanced HCC [40].

Analytical, diagnostic and therapeutic context of HCC

  • METHODS: An observational follow-up cohort study of HCC cases diagnosed over a five-year period was carried out [4].
  • PURPOSE: We conducted a case-control study to estimate the relative risk (RR) of HCC in relation to HCV infection among residents of the Fukuoka Prefecture, where HCC risk is among the highest in Japan, and to examine whether the risk differs according to HCV genotypes and/or HCV RNA titers [8].
  • Surveillance plus chemoprevention in cirrhotic patients with HCV: a better outlook for HCC [41]?
  • In six (50%), HCC developed, compared with 2 (8%) from a control group consisting of 24 patients without IFF matched according to age, sex, degree of fibrosis, liver iron amount and follow-up duration [42].
  • DCP levels greater than 0.1 AU/ml (100 ng/ml) on ELISA are highly suggestive of HCC or tumor recurrence [43].


  1. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Looi, K., Megliorino, R., Shi, F.D., Peng, X.X., Chen, Y., Zhang, J.Y. Oncol. Rep. (2006) [Pubmed]
  2. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Park, J.H., Koh, K.C., Choi, M.S., Lee, J.H., Yoo, B.C., Paik, S.W., Rhee, J.C., Joh, J.W. Am. J. Surg. (2006) [Pubmed]
  3. Extreme elevation of serum alpha fetoprotein in decompensated cirrhosis without HCC: an ominous sign. Senturk, H., Cumali, R. Int. J. Biol. Markers (2007) [Pubmed]
  4. Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. Yaghi, C., Sharara, A.I., Rassam, P., Moucari, R., Honein, K., BouJaoude, J., Slim, R., Noun, R., Abdul-Baki, H., Khalifeh, M., Ramia, S., Sayegh, R. World J. Gastroenterol. (2006) [Pubmed]
  5. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. Chantajitr, S., Wilasrusmee, C., Lertsitichai, P., Phromsopha, N. Journal of hepato-biliary-pancreatic surgery (2006) [Pubmed]
  6. Hepatitis C and alcohol. Degos, F. J. Hepatol. (1999) [Pubmed]
  7. Screening for cancer in viral hepatitis. Colombo, M. Clinics in liver disease. (2001) [Pubmed]
  8. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. Tanaka, K., Ikematsu, H., Hirohata, T., Kashiwagi, S. J. Natl. Cancer Inst. (1996) [Pubmed]
  9. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Paradis, V., Bièche, I., Dargère, D., Laurendeau, I., Nectoux, J., Degott, C., Belghiti, J., Vidaud, M., Bedossa, P. Gastroenterology (2003) [Pubmed]
  10. Histocompatibility antigens in patients with hepatocellular carcinoma and their relationship to chronic hepatitis B virus infection in these patients. Kew, M.C., Gear, A.J., Baumgarten, I., Dusheiko, G.M., Maier, G. Gastroenterology (1979) [Pubmed]
  11. Vibrational and electronic spectra of neutral and ionic combustion reaction intermediates trapped in rare-gas matrixes. Jacox, M.E. Acc. Chem. Res. (2004) [Pubmed]
  12. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Xu, J., Shen, Z.Y., Chen, X.G., Zhang, Q., Bian, H.J., Zhu, P., Xu, H.Y., Song, F., Yang, X.M., Mi, L., Zhao, Q.C., Tian, R., Feng, Q., Zhang, S.H., Li, Y., Jiang, J.L., Li, L., Yu, X.L., Zhang, Z., Chen, Z.N. Hepatology (2007) [Pubmed]
  13. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. Livraghi, T., Bolondi, L., Buscarini, L., Cottone, M., Mazziotti, A., Morabito, A., Torzilli, G. J. Hepatol. (1995) [Pubmed]
  14. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Jhawer, M., Rosen, L., Dancey, J., Hochster, H., Hamburg, S., Tempero, M., Clendeninn, N., Mani, S. Investigational new drugs (2007) [Pubmed]
  15. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Cammà, C., Di Bona, D., Craxì, A. Curr. Pharm. Des. (2004) [Pubmed]
  16. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Ren, X.W., Liang, M., Meng, X., Ye, X., Ma, H., Zhao, Y., Guo, J., Cai, N., Chen, H.Z., Ye, S.L., Hu, F. Cancer Gene Ther. (2006) [Pubmed]
  17. Conformational effects on optical rotation. 2-Substituted butanes. Wiberg, K.B., Wang, Y.G., Vaccaro, P.H., Cheeseman, J.R., Luderer, M.R. The journal of physical chemistry. A, Molecules, spectroscopy, kinetics, environment & general theory. (2005) [Pubmed]
  18. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Zhang, Y.J., Rossner, P., Chen, Y., Agrawal, M., Wang, Q., Wang, L., Ahsan, H., Yu, M.W., Lee, P.H., Santella, R.M. Int. J. Cancer (2006) [Pubmed]
  19. Changes in natural killer T cells subsets during therapy in type C hepatitis and hepatocellular carcinoma. Okumura, A., Ishikawa, T., Maeno, T., Sato, K., Ayada, M., Hotta, N., Yamauchi, T., Fukuzawa, Y., Kakumu, S. Hepatol. Res. (2005) [Pubmed]
  20. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Coulouarn, C., Gomez-Quiroz, L.E., Lee, J.S., Kaposi-Novak, P., Conner, E.A., Goldina, T.A., Onishchenko, G.E., Factor, V.M., Thorgeirsson, S.S. Hepatology (2006) [Pubmed]
  21. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Sasaki, A., Iwashita, Y., Shibata, K., Matsumoto, T., Ohta, M., Kitano, S. Surgery (2006) [Pubmed]
  22. An update on iron metabolism: summary of the Fifth International Conference on Disorders of Iron Metabolism. Bonkovsky, H.L., Ponka, P., Bacon, B.R., Drysdale, J., Grace, N.D., Tavill, A.S. Hepatology (1996) [Pubmed]
  23. Characteristics of a cell line (Tong/HCC) established from a human hepatocellular carcinoma. Stevenson, D., Lin, J.H., Tong, M.J., Marshall, G.J. Hepatology (1987) [Pubmed]
  24. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. Leidenius, M., Höckersted, K., Broomé, U., Ericzon, B.G., Friman, S., Olausson, M., Schrumpf, E. J. Hepatol. (2001) [Pubmed]
  25. T cell infiltration and prognosis in HCC patients. Parmiani, G., Anichini, A. J. Hepatol. (2006) [Pubmed]
  26. Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study. Becker, G., Allgaier, H.P., Olschewski, M., Z??hringer, A., Blum, H.E. Hepatology (2007) [Pubmed]
  27. Genome-wide hypomethylation in hepatocellular carcinogenesis. Lin, C.H., Hsieh, S.Y., Sheen, I.S., Lee, W.C., Chen, T.C., Shyu, W.C., Liaw, Y.F. Cancer Res. (2001) [Pubmed]
  28. Chemical carcinogenesis: mycotoxins and other chemicals to which humans are exposed. Newberne, P.M. Semin. Liver Dis. (1984) [Pubmed]
  29. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Yuan, J.M., Ross, R.K., Stanczyk, F.Z., Govindarajan, S., Gao, Y.T., Henderson, B.E., Yu, M.C. Int. J. Cancer (1995) [Pubmed]
  30. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Masaki, T., Tokuda, M., Yoshida, S., Nakai, S., Morishita, A., Uchida, N., Funaki, T., Kita, Y., Funakoshi, F., Nonomura, T., Himoto, T., Deguchi, A., Kimura, Y., Izuishi, K., Wakabayashi, H., Usuki, H., Yoshiji, H., Watanabe, S., Kurokohchi, K., Kuriyama, S. Int. J. Oncol. (2005) [Pubmed]
  31. Evidence that "myofibroblast-like" cells are the cellular source of capsular collagen in hepatocellular carcinoma. Ooi, L.P., Crawford, D.H., Gotley, D.C., Clouston, A.D., Strong, R.W., Gobe, G.C., Halliday, J.W., Bridle, K.R., Ramm, G.A. J. Hepatol. (1997) [Pubmed]
  32. CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens. Chan, R.C., Xie, Y. Oncol. Rep. (2004) [Pubmed]
  33. Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Khoury, T., Chadha, K., Javle, M., Donohue, K., Levea, C., Iyer, R., Okada, H., Nagase, H., Tan, D. International journal of gastrointestinal cancer. (2005) [Pubmed]
  34. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system. Wang, X.Z., Chen, X.C., Chen, Y.X., Zhang, L.J., Li, D., Chen, F.L., Chen, Z.X., Chen, H.Y., Tao, Q.M. World J. Gastroenterol. (2003) [Pubmed]
  35. Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. Xiao, Y., Kleeff, J., Guo, J., Gazdhar, A., Liao, Q., Di Cesare, P.E., Büchler, M.W., Friess, H. J. Gastroenterol. Hepatol. (2004) [Pubmed]
  36. A panel of molecular markers in hepatitis C virus-related hepatocellular carcinoma. Elgendy, S.M., Hessien, M., Elsherbiny, M.M., Abd El-Salam, I.M., El-Attar, I.A., El-Asser, A.e.l.-.B. Journal of the Egyptian National Cancer Institute (2005) [Pubmed]
  37. Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells. Hsieh, S.Y., Liaw, S.F., Lee, S.N., Hsieh, P.S., Lin, K.H., Chu, C.M., Liaw, Y.F. Br. J. Cancer (2003) [Pubmed]
  38. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. Kim, J.R., Kim, C.H. Int. J. Biochem. Cell Biol. (2004) [Pubmed]
  39. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Raderer, M., Hejna, M.H., Muller, C., Kornek, G.V., Kurtaran, A., Virgolini, I., Fiebieger, W., Hamilton, G., Scheithauer, W. Int. J. Oncol. (2000) [Pubmed]
  40. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Jonas, S., Bechstein, W.O., Heinze, T., Kling, N., Lobeck, H., Tullius, S.G., Steinmueller, T., Neuhaus, P. Surgery (1997) [Pubmed]
  41. Surveillance plus chemoprevention in cirrhotic patients with HCV: a better outlook for HCC? Blendis, L. Gastroenterology (2004) [Pubmed]
  42. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Deugnier, Y.M., Charalambous, P., Le Quilleuc, D., Turlin, B., Searle, J., Brissot, P., Powell, L.W., Halliday, J.W. Hepatology (1993) [Pubmed]
  43. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Weitz, I.C., Liebman, H.A. Hepatology (1993) [Pubmed]
WikiGenes - Universities